Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2019

20.05.2019 | Epidemiology

Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy

verfasst von: Lynn Jongen, Giuseppe Floris, Hans Wildiers, Frank Claessens, François Richard, Annouschka Laenen, Christine Desmedt, Jan Ardui, Kevin Punie, Ann Smeets, Patrick Berteloot, Ignace Vergote, Patrick Neven

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess clinical pathological characteristics and outcome of triple-negative breast cancers (TNBC) by androgen receptor (AR) protein expression.

Methods

We retrospectively evaluated AR by immunohistochemistry on core-needle biopsy, (CNB) and residual disease (RD) in a consecutive institutional series of TNBC patients treated with neo-adjuvant chemotherapy (NACT) between 2000 and 2017. We investigated univariate associations between AR-expression on CNB (using different cut-offs), clinical pathological variables, and pathologic complete response (pCR). Next, we used multiple correspondence analysis (MCA) to investigate the relationships between AR on CNB and standard clinical and pathological variables, including stromal tumor infiltrating lymphocytes (sTILs). Finally, we investigated the prognostic value of AR-expression on CNB and RD using the Fine and Gray model.

Results

We included 71 patients; median follow-up was 6.7 years. Considering the ≥ 1% cut-off, AR was present in 32% on the CNB and 14% on RD. AR-low (1-34% positive tumor cells) patients were associated with younger (premenopausal) age and AR-high (≥ 34% positive tumor cells) with older (postmenopausal) age. AR on CNB did not correlate with other features nor was it predictive for pCR or prognostic for metastatic outcome, regardless of the used cut-off. The MCA suggested that body mass index (BMI) affects the predictive role of AR-low and -high for pCR differently. AR-loss on RD was prognostic for a better 5-year distant disease-free survival (DDFS) as compared to RD with retained AR-expression (61.6% (95% CI 44.26–79.14) and 25.0% (95% CI 3.94–87.21), respectively; p = 0.01).

Conclusion

Low and high AR-expression on CNB of TNBC were correlated with age and menopausal status but qualitative AR was not predictive for pCR. AR-loss on RD was prognostic for DDFS in TNBC patients treated with NACT.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Brouckaert O, Laenen A, Vanderhaegen J et al (2012) Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol 23:2578–2584CrossRef Brouckaert O, Laenen A, Vanderhaegen J et al (2012) Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol 23:2578–2584CrossRef
2.
Zurück zum Zitat Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502CrossRef Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502CrossRef
3.
Zurück zum Zitat Prat A, Pineda E, Adamo B et al (2015) Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24(Suppl 2):S26–35CrossRef Prat A, Pineda E, Adamo B et al (2015) Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24(Suppl 2):S26–35CrossRef
4.
Zurück zum Zitat Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108–2121CrossRef Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108–2121CrossRef
5.
Zurück zum Zitat Collins LC, Cole KS, Marotti JD et al (2011) Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 24:924–931CrossRef Collins LC, Cole KS, Marotti JD et al (2011) Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 24:924–931CrossRef
6.
Zurück zum Zitat He J, Peng R, Yuan Z et al (2012) Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 29:406–410CrossRef He J, Peng R, Yuan Z et al (2012) Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 29:406–410CrossRef
7.
Zurück zum Zitat Qi JP, Yang YL, Zhu H et al (2012) Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. Breast Cancer (Auckl) 6:1–8 Qi JP, Yang YL, Zhu H et al (2012) Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. Breast Cancer (Auckl) 6:1–8
8.
Zurück zum Zitat Tang D, Xu S, Zhang Q, Zhao W (2012) The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 29:526–533CrossRef Tang D, Xu S, Zhang Q, Zhao W (2012) The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 29:526–533CrossRef
9.
Zurück zum Zitat Choi JE, Kang SH, Lee SJ, Bae YK (2015) Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 22:82–89CrossRef Choi JE, Kang SH, Lee SJ, Bae YK (2015) Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 22:82–89CrossRef
10.
Zurück zum Zitat Agoff SN, Swanson PE, Linden H et al (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120:725–731CrossRef Agoff SN, Swanson PE, Linden H et al (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120:725–731CrossRef
11.
Zurück zum Zitat Gonzalez-Angulo AM, Stemke-Hale K, Palla SL et al (2009) Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15:2472–2478CrossRef Gonzalez-Angulo AM, Stemke-Hale K, Palla SL et al (2009) Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15:2472–2478CrossRef
12.
Zurück zum Zitat Peters AA, Buchanan G, Ricciardelli C et al (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69:6131–6140CrossRef Peters AA, Buchanan G, Ricciardelli C et al (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 69:6131–6140CrossRef
13.
Zurück zum Zitat Hu R, Dawood S, Holmes MD et al (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17:1867–1874CrossRef Hu R, Dawood S, Holmes MD et al (2011) Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 17:1867–1874CrossRef
14.
Zurück zum Zitat Denkert C, Loibl S, Noske A et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105–113CrossRef Denkert C, Loibl S, Noske A et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105–113CrossRef
15.
Zurück zum Zitat Huober J, von Minckwitz G, Denkert C et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124:133–140CrossRef Huober J, von Minckwitz G, Denkert C et al (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124:133–140CrossRef
16.
Zurück zum Zitat Gerber B, Loibl S, Eidtmann H et al (2013) Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 24:2978–2984CrossRef Gerber B, Loibl S, Eidtmann H et al (2013) Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 24:2978–2984CrossRef
17.
Zurück zum Zitat Bonsang-Kitzis H, Chaltier L, Belin L et al (2015) Beyond axillary lymph node metastasis, BMI and menopausal status are prognostic determinants for triple-negative breast cancer treated by neoadjuvant chemotherapy. PLoS ONE 10:e0144359CrossRef Bonsang-Kitzis H, Chaltier L, Belin L et al (2015) Beyond axillary lymph node metastasis, BMI and menopausal status are prognostic determinants for triple-negative breast cancer treated by neoadjuvant chemotherapy. PLoS ONE 10:e0144359CrossRef
18.
Zurück zum Zitat Widschwendter P, Friedl TW, Schwentner L et al (2015) The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 17:129CrossRef Widschwendter P, Friedl TW, Schwentner L et al (2015) The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 17:129CrossRef
19.
Zurück zum Zitat Hao S, Liu Y, Yu KD et al (2015) Overweight as a prognostic factor for triple-negative breast cancers in chinese women. PLoS ONE 10:e0129741CrossRef Hao S, Liu Y, Yu KD et al (2015) Overweight as a prognostic factor for triple-negative breast cancers in chinese women. PLoS ONE 10:e0129741CrossRef
20.
Zurück zum Zitat Masili-Oku SM, Almeida BGL, Bacchi CE et al (2017) Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: lower expression of basal immunohistochemical markers. Breast 31:34–39CrossRef Masili-Oku SM, Almeida BGL, Bacchi CE et al (2017) Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: lower expression of basal immunohistochemical markers. Breast 31:34–39CrossRef
21.
Zurück zum Zitat Denkert C, von Minckwitz G, Brase JC et al (2015) Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33:983–991CrossRef Denkert C, von Minckwitz G, Brase JC et al (2015) Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33:983–991CrossRef
22.
Zurück zum Zitat Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767CrossRef Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767CrossRef
23.
Zurück zum Zitat Santonja A, Sanchez-Munoz A, Lluch A et al (2018) Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget 9:26406–26416CrossRef Santonja A, Sanchez-Munoz A, Lluch A et al (2018) Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget 9:26406–26416CrossRef
24.
Zurück zum Zitat Gucalp A, Tolaney S, Isakoff SJ et al (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 19:5505–5512CrossRef Gucalp A, Tolaney S, Isakoff SJ et al (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 19:5505–5512CrossRef
25.
Zurück zum Zitat Traina TA, Miller K, Yardley DA et al (2015) Results from a phase 2 study of enzalutamide, an androgen receptor inhibitor, in advanced AR+ Triple-negative breast cancer (MDV3100-11). In ASCO 2015 Traina TA, Miller K, Yardley DA et al (2015) Results from a phase 2 study of enzalutamide, an androgen receptor inhibitor, in advanced AR+ Triple-negative breast cancer (MDV3100-11). In ASCO 2015
26.
Zurück zum Zitat Liu CY, Lau KY, Hsu CC et al (2017) Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. PLoS ONE 12:e0189007CrossRef Liu CY, Lau KY, Hsu CC et al (2017) Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. PLoS ONE 12:e0189007CrossRef
27.
Zurück zum Zitat Lehmann BD, Bauer JA, Schafer JM et al (2014) PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 16:406CrossRef Lehmann BD, Bauer JA, Schafer JM et al (2014) PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 16:406CrossRef
28.
Zurück zum Zitat Jongen L, Paridaens R, Floris G et al (2016) Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm. Breast Cancer Res Treat 15:603–607CrossRef Jongen L, Paridaens R, Floris G et al (2016) Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm. Breast Cancer Res Treat 15:603–607CrossRef
29.
Zurück zum Zitat Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795CrossRef Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795CrossRef
30.
Zurück zum Zitat Astvatsaturyan K, Yue Y, Walts AE, Bose S (2018) Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. PLoS ONE 13:e0197827CrossRef Astvatsaturyan K, Yue Y, Walts AE, Bose S (2018) Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. PLoS ONE 13:e0197827CrossRef
31.
Zurück zum Zitat Thike AA, Yong-Zheng Chong L, Cheok PY et al (2014) Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol 27:352–360CrossRef Thike AA, Yong-Zheng Chong L, Cheok PY et al (2014) Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol 27:352–360CrossRef
32.
Zurück zum Zitat Park S, Koo JS, Kim MS et al (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 22:1755–1762CrossRef Park S, Koo JS, Kim MS et al (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 22:1755–1762CrossRef
33.
Zurück zum Zitat Micello D, Marando A, Sahnane N et al (2010) Androgen receptor is frequently expressed in HER2-positive. ER/PR-negative breast cancers. Virchows Arch 457:467–476CrossRef Micello D, Marando A, Sahnane N et al (2010) Androgen receptor is frequently expressed in HER2-positive. ER/PR-negative breast cancers. Virchows Arch 457:467–476CrossRef
34.
Zurück zum Zitat Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259–271CrossRef Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259–271CrossRef
35.
Zurück zum Zitat Loi S, Drubay D, Adams S et al (2019) Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37:559–569CrossRef Loi S, Drubay D, Adams S et al (2019) Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37:559–569CrossRef
36.
Zurück zum Zitat Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422CrossRef Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422CrossRef
37.
Zurück zum Zitat Masuda H, Baggerly KA, Wang Y et al (2013) Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19:5533–5540CrossRef Masuda H, Baggerly KA, Wang Y et al (2013) Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19:5533–5540CrossRef
38.
Zurück zum Zitat Jovanovic B, Mayer IA, Mayer EL et al (2017) A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin Cancer Res 23:4035–4045CrossRef Jovanovic B, Mayer IA, Mayer EL et al (2017) A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin Cancer Res 23:4035–4045CrossRef
39.
Zurück zum Zitat Glisch C, Jawa ZA, Badar T et al (2018) Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: a single institution experience. J Clin Oncol 36:e12662–e12662CrossRef Glisch C, Jawa ZA, Badar T et al (2018) Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: a single institution experience. J Clin Oncol 36:e12662–e12662CrossRef
40.
Zurück zum Zitat Mrklic I, Pogorelic Z, Capkun V, Tomic S (2013) Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem 115:344–348CrossRef Mrklic I, Pogorelic Z, Capkun V, Tomic S (2013) Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem 115:344–348CrossRef
41.
Zurück zum Zitat McGhan LJ, McCullough AE, Protheroe CA et al (2014) Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol 21:361–367CrossRef McGhan LJ, McCullough AE, Protheroe CA et al (2014) Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol 21:361–367CrossRef
42.
Zurück zum Zitat Loibl S, Müller BM, von Minckwitz G et al (2011) Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 130:477–487CrossRef Loibl S, Müller BM, von Minckwitz G et al (2011) Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 130:477–487CrossRef
43.
Zurück zum Zitat Sun L, Zhu Y, Qian Q, Tang L (2018) Body mass index and prognosis of breast cancer: an analysis by menstruation status when breast cancer diagnosis. Medicine 97:e11220–e11220CrossRef Sun L, Zhu Y, Qian Q, Tang L (2018) Body mass index and prognosis of breast cancer: an analysis by menstruation status when breast cancer diagnosis. Medicine 97:e11220–e11220CrossRef
44.
Zurück zum Zitat Baglietto L, English DR, Hopper JL et al (2009) Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat 115:171–179CrossRef Baglietto L, English DR, Hopper JL et al (2009) Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat 115:171–179CrossRef
45.
Zurück zum Zitat Macinnis RJ, English DR, Gertig DM et al (2004) Body size and composition and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 13:2117–2125PubMed Macinnis RJ, English DR, Gertig DM et al (2004) Body size and composition and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 13:2117–2125PubMed
46.
Zurück zum Zitat Wang C, Pan B, Zhu H et al (2016) Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget 7:46482–46491PubMedPubMedCentral Wang C, Pan B, Zhu H et al (2016) Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget 7:46482–46491PubMedPubMedCentral
47.
Zurück zum Zitat Qu Q, Mao Y, Fei XC, Shen KW (2013) The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS ONE 8:e82650CrossRef Qu Q, Mao Y, Fei XC, Shen KW (2013) The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS ONE 8:e82650CrossRef
48.
Zurück zum Zitat Parinyanitikul N, Lei X, Chavez-MacGregor M et al (2015) Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer 15:153–160CrossRef Parinyanitikul N, Lei X, Chavez-MacGregor M et al (2015) Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer 15:153–160CrossRef
49.
Zurück zum Zitat Dawood S, Gonzalez-Angulo AM (2012) Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer. Cancer Biomark 12:241–250CrossRef Dawood S, Gonzalez-Angulo AM (2012) Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer. Cancer Biomark 12:241–250CrossRef
50.
Zurück zum Zitat Liu YX, Zhang KJ, Tang LL (2018) Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study. Oncol Lett 15:10008–10016PubMedPubMedCentral Liu YX, Zhang KJ, Tang LL (2018) Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study. Oncol Lett 15:10008–10016PubMedPubMedCentral
Metadaten
Titel
Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy
verfasst von
Lynn Jongen
Giuseppe Floris
Hans Wildiers
Frank Claessens
François Richard
Annouschka Laenen
Christine Desmedt
Jan Ardui
Kevin Punie
Ann Smeets
Patrick Berteloot
Ignace Vergote
Patrick Neven
Publikationsdatum
20.05.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05252-6

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Research and Treatment 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.